reflections on the global generic pharmaceuticals market place l.
Skip this Video
Loading SlideShow in 5 Seconds..
Reflections on the Global Generic Pharmaceuticals Market place PowerPoint Presentation
Download Presentation
Reflections on the Global Generic Pharmaceuticals Market place

Loading in 2 Seconds...

play fullscreen
1 / 33

Reflections on the Global Generic Pharmaceuticals Market place - PowerPoint PPT Presentation

  • Uploaded on

Reflections on the Global Generic Pharmaceuticals Market place. Dr. Brian W Tempest CII Pharma Summit Mumbai Thursday November 1 st 2007. DR. BRIAN W. TEMPEST CSci, CChem, MRSC, BSc, PhD

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Reflections on the Global Generic Pharmaceuticals Market place' - chesna

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
reflections on the global generic pharmaceuticals market place

Reflections on the Global Generic Pharmaceuticals Market place

Dr. Brian W Tempest

CII Pharma Summit Mumbai

Thursday November 1st 2007



Dr. Brian Tempest has worked in the pharma industry for the last 36 years. During this time he has worked for several pharma majors, including Glaxo & Searle, around the world and joined Ranbaxy 12 years ago. During this period Ranbaxy has transformed from a small company focused on the India domestic market, to a top 10 global generic company. Dr. Tempest has lived in New Delhi, India for the last 8 years, and has been President, Managing Director & Chief Executive Officer and, until recently, the Chief Mentor & Executive Vice Chairman of the Board. Dr. Tempest retired from Ranbaxy in December 2007, when he reached 60. Dr. Tempest is one of a few westerners to have held a leadership position in an Indian blue chip MNC, and has an unusual insight into India.

Dr Tempest is also a Honorary Professor of the Management School at Lancaster University, UK, and he sits on the Editorial Board of the Journal of Generic Medicines and on the Advisory Board of the India Fund held by JM Financial Investment Managers Ltd in Mumbai.

Dr. Tempest is exclusively supplied by ‘Hale & Tempest Co. Ltd’ /

Mobile +91-98100-91192 / Tel:+44 1753 864 616

asia on the rise
Asia on the Rise

Source – FT

  • Market drivers
  • Competition is rising
  • Branded generics
  • IP changes in USA & India
  • M&A and Private Equity
  • East-West Alliances

The Productivity Advantage

India a usa Pharma view USA

1 chemist Better education x 1.3 1 chemist

70 hours/week Longer working time x 1.3 50 hours/week

$ 800 monthly Lower cost x 20 $ 12,000 monthly

Sources: IPHMR Conferences, New Delhi August 2004


Top 5 Global Pharmaceutical Markets 2020

Sources: Goldman Sachs 2007


Patent Expiry Dates








% at Risk

Sources: AXA Framlington

competition is rising cphi attendees milan 2 nd 4 th oct 07
Competition is Rising CPHI Attendees, Milan,2nd – 4th Oct’07

As registered on July 25, 2007


Generics – API’s

USA DMF filings by India

% Share of USA DMF filings


2004 27% 9%

2005 37% 10%

2006 44% 14%

Q1’07 48% 17%

Source: US FDA / J P Morgan, 2 may 2007


2004 187 48

2005 252 87

2006 357 128

Source: US FDA / J P Morgan, 6th August 2006

Source: US FDA, Credit Suisse


Generics - ANDAs

- One in every four ANDAs filed by Indian Companies in top

USA FDA filers

Source: KPMG

- First Chinese generic company has received tentative FDA


ANDA Filings in USA by Indian Companies






speed of clinical trials in india
Speed of Clinical Trials in India


Patients 85 650

Sites 22 5

Time 36m 18m

Neck Cancer CT

Plan Actual

Patients 100 130

Sites 10 9

Time 5m 2.5m

Overactive bladder CT

  • No. of USA investigators:

2001 - 2006

26,000 18,000

  • 300 patients, 30 sites

$5.6m EU/USA vs $ 1.8m plus

30% faster at $800K per day savings

Sources: CT Outsourcing Conference, 24th July 2007, Mumbai

electronic data capture in india
Electronic Data Capture in India


- 300 GSK Staff

- 2.2m Clinical Data sheets

- 450 Trials

- No data security issues

- Error rate <0.01 / 100k

Source: BCG report “Looking Eastward, Sept’2006”

% Trials in EDC

2005 2007

25% 45%


Paper EDC

$2.8m $ 0.5m

2004 data

Sources: CT Outsourcing Conference,

24th July 2007, Mumbai

branded generics the analyst s view
Branded Generics - the Analyst’s view
  • “Branded Generics are the most profitable place to be in generics and there are a few markets with better branded characteristics than those of the Middle East and North Africa region”

Frances Cloud Nomura September 14 2007

ip usa pendulum
IP – USA Pendulum
  • “A key USA Supreme Court ruling KSR VS Teleflex led to Pharmaceutical patents being more easily challenged on the grounds of obviousness, a ruling which immediately came into play when J&J & Merck had a US patent for Pepcid Complete (Famotodine) found to be obvious”.
  • Scrip, July 6th 2007, p3
  • The full beneficial impact of this ruling on the generic industry is yet to be seen eg Sanofi-Aventis Ramipril was invalidated as obvious by Lupin in September 2007.
bilateral ftas usa pendulum
Bilateral FTAs - USA Pendulum
  • Democrats now chairing Committees- Ways & Means
  • USTR legally required to work within TRIPS
  • USA has been incorporating TRIPS PLUS IP protection into bilateral free trade agreements
  • Corrections to bilateral trade agreements eg Peru, Columbia, Panama FTAs


  • Basic product patent
  • Data protection


+ Data exclusivity

+ New forms, isomers etc

+ New Indications

+ New Combinations

should ip be the same across all countries
Should IP be the same across all Countries?


Per Capita Expenditure on Healthcare 2002






Sources: World Health Report 2005

enforcement versus evergreening in developing countries
Enforcement versus Evergreeningin Developing Countries

India IP 02/03 06//07

Filed 11466 28882

Examined 9538 14119

Granted 1379 7359

- 140 patent examiners 2007

- 600 more planned

- Attrition an issue

- Weekly patent journal

- IP Appellate Court

Source: Business Standard, 16th Aug’2007

  • 1995 – 2005 FDA cleared 327 drugs
  • 95% pre 1995 – before WTO deal
  • 16 basic patent molecules possible
  • However 9000 Pharma applications
  • - for evergreen changes
  • - for new indications

Source: Gopa Kumar

“Centre for Trade & Development, Delhi”

pe deals in asia ex japan in h1 2007
PE Deals in Asia (ex-Japan) in H1 2007

Sources: Thomson Financial

the tempest crystal ball
The Tempest Crystal Ball
  • India will continue to be a Key Driver in the Global Generic Industry
  • Competition is rising – Post TRIPs Indian companies will evolve
  • Discovery companies will continue to be attracted to India for CT, EDC,
  • MO. China will be perceived to be stronger in biology/ toxicology
  • IP changes in US & India will slowly favor Generics
  • Alliances between Western Biotech and Asians companies will expand.
  • M&A PE deals will grow
  • How to use Asia will become the key opportunity

The rise of the Indian Middle Class

- Assumes GDP growth of 7.3% for next 20 years with no profound shift in economic policy

Sources: McKinsey Quarterly, 3rd November 2007



Asia economic strength is returning to levels seen in the past

Many advantages for India with some challenges

India is a global strategic asset for developed markets

India is a rich location for R&D alliances and CT outsourcing

MNCs will dip in & out of India & China

South East Asian economies will be driven by India & China

Japan will continue to represent a huge share of global wealth

“China & India represent the future of Asia and quite possibly the future for the global economy” – Steve Roach, Morgan Stanley